` CELC (Celcuity Inc) vs S&P 500 Comparison - Alpha Spread

C
CELC
vs
S&P 500

Over the past 12 months, CELC has significantly outperformed S&P 500, delivering a return of +716% compared to the S&P 500's +14% growth.

Stocks Performance
CELC vs S&P 500

Loading
CELC
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CELC vs S&P 500

Performance Gap Between CELC and GSPC
HIDDEN
Show

Performance By Year
CELC vs S&P 500

Loading
CELC
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Celcuity Inc vs Peers

S&P 500
CELC
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Celcuity Inc
Glance View

Market Cap
4.4B USD
Industry
Biotechnology

Celcuity, Inc. is cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 39 full-time employees. The company went IPO on 2017-09-20. The firm is focused on discovering cancer sub-types molecular-based approaches through developing companion diagnostic tests (CDx) and therapeutic (Rx). The firm's product pipeline includes CELsignia platform and Gedatolisib. The CELsignia diagnostic platform is used to analyze live patient tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy. The CELsignia platform provides traditional molecular diagnostics, which includes snapshot of the genetic mutations present in a patients tumor because they analyze cell fragments and molecular diagnostics can estimate the patients potential drug response based on a statistical analysis of the drugs clinical trial result. Its other product candidate includes Gedatolisib, is a small molecule dual inhibitor, administered intravenously, that targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR).

CELC Intrinsic Value
HIDDEN
Show
Back to Top